i-SENS Inc

What i-SENS Inc does

i-SENS Inc. ((주)아이센스) is a South Korean in vitro diagnostics (IVD) company, founded May 4, 2000 and listed on KOSDAQ under ticker 099190, that develops and manufactures electrochemical biosensor products for diabetes management and adjacent point-of-care diagnostics. The company sells through four product lines — self blood glucose meters (BGM) under the CareSens brand, continuous glucose monitoring systems (CGM) under the CareSens Air brand including the next-generation CareSens Air 2, point-of-care testing (POCT) analyzers including the A1Care clinical chemistry analyzer, and veterinary diagnostic devices — with a connected Sens365 data platform (mobile app, statistics app, web portal) including integration with Samsung Health.

Manufacturing is concentrated at two automated plants in Songdo, Incheon, with annual capacity of 2.1 billion BGM test strips and up to 5.4 million CGM sensor units (Songdo Plant 2 ramped from 500,000 to 2 million CGM units following a KRW 200B investment). The company holds Korea MFDS approval, CE marking, FDA investigational trial status (CareSens Air 2, FPI Feb 17, 2026), and national reimbursement listings in 10+ countries. Its products reach 110+ countries through a hybrid go-to-market combining a direct-to-consumer CareSens Mall e-commerce channel, retail pharmacy distribution, the wholly-owned AgaMatrix UK subsidiary, a LifeScan private-label channel partnership for OneTouch-branded CGM in select European markets from early 2027, and national insurance reimbursement across Korea (NHIS), UK, Germany, Belgium (INAMI), and others.

In 2025, i-SENS reported KRW 315.7B in consolidated revenue and KRW 83B in operating profit, with the CGM segment contributing KRW 176B (exceeding the KRW 150B target) and Q1 2026 CGM revenue of KRW 84B (+172% YoY). The CareSens brand has held the top position in Korea's BGM market for 13+ consecutive years, and the company has stated a target of 10% global CGM market share in the 2030s. Co-Representatives Cha Geun-sik and Nam Hak-hyeon lead the company.

Name

i-SENS Inc

Legal name

(주)아이센스

Website

https://i-sens.co.kr

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

501–1,000 employees

Short description

i-SENS Inc. is a South Korean KOSDAQ-listed IVD company that manufactures electrochemical biosensor products for diabetes management — CareSens blood glucose meters, CareSens Air continuous glucose monitors, and point-of-care and veterinary diagnostics — serving patients and healthcare providers across 110+ countries.

Ownership category

akta.pro rank

Product category

Blood Glucose Monitoring Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)

akta.pro secondary industries

Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

Keywords

• Blood glucose monitoring
• Continuous glucose monitoring
• Biosensor diagnostics
• Point-of-care testing
• Veterinary diagnostics

Headquarters

HQ city

Seocho

HQ country

South Korea

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Blood Glucose Monitoring (BGM) Products: Sale of blood glucose meters and test strips. CareSens brand products including CareSens N, CareSens N Voice, CareSens Dual. ISO 15197:2013 accuracy compliance.
2. Continuous Glucose Monitoring (CGM) Products: Sale of CGM sensors and related consumables. CareSens Air and CareSens Air 2 products. Insurance reimbursement channels in multiple countries including Korea, UK, Germany, Belgium, Estonia, Hungary, Poland, Czech Republic, Croatia, Israel.
3. Private Label CGM Supply: CGM product supply contracts with global partners under their brands. LifeScan partnership to supply CGM products under OneTouch Vita brand in European markets.
4. Point of Care Testing (POCT) Products: Blood gas and electrolyte analyzers, immunoassay analyzers for rapid diagnostic solutions
5. Veterinary Diagnostic Products: Various field diagnostic equipment for animal health assessment

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

i-SENS manufactures and sells electrochemical biosensor-based medical diagnostic devices, primarily blood glucose meters (CareSens BGM brand) and test strips, continuous glucose monitoring systems (CareSens Air and CareSens Air 2 sensors) with companion smartphone applications, point-of-care clinical chemistry analyzers (A1Care), and veterinary diagnostic equipment. Products are sold both directly to diabetes patients and through healthcare institutions, channel partners, and national insurance reimbursement programs across 110+ countries.

Product overview

i-SENS Inc is a global in vitro diagnostics (IVD) company specializing in biosensor technology for blood glucose management. Its product portfolio spans four main categories: (1) Continuous Glucose Monitoring Systems (CGMS) centered on the CareSens Air platform, including the next-generation CareSens Air 2; (2) Self-Blood Glucose Monitoring Systems (BGM) under the CareSens brand, encompassing devices like CareSens N (with voice/sign-language accessibility variants) and CareSens Dual; (3) Point-of-Care Testing (POCT) including the A1Care clinical chemistry analyzer and immunochemistry analyzers; and (4) Veterinary diagnostic solutions. All CGM and BGM products are connected to the Sens365 data platform ecosystem — comprising a mobile app for real-time glucose tracking, a statistics app, and a web portal for healthcare provider data sharing. The company operates primarily in Korea and exports to over 110 countries.

Differentiator

Problem solved

Functional benefit

Brands

• CareSens (케어센스): Blood glucose monitoring system brand; self-monitoring blood glucose meters (BGM); won 'Brand of the Year' award 13+ consecutive years in Korea
• CareSens Air (케어센스 에어)
• Sens365
• CareSens Dual
• CareSens N Premier
• CareSens N Voice (케어센스 N 보이스)
• A1Care

Products and services

• CareSens Air (케어센스 에어) Continuous Glucose Monitoring System Korea's first domestically developed continuous glucose monitoring system that measures interstitial fluid glucose every 5 minutes via a body-worn sensor with up to 15 days wear duration, transmitting real-time data via Bluetooth to a companion smartphone app. Waterproof at 1m depth for 24 hours. Targets diabetes patients needing continuous glucose trend data, with data sharing capabilities for healthcare providers.
• CareSens Air 2 (케어센스 에어 2) Next-Generation CGM Next-generation CGM sensor with extended 18-day wear duration, approximately 70% smaller sensor volume, and reduced 20-minute initial stabilization time. Targets diabetes patients globally with planned launches in Korea and Europe in Q1 2027. Includes physical display and Bluetooth smartwatch app support.
• CareSens (케어센스) Blood Glucose Monitoring System Self-blood glucose monitoring system brand. CareSens meters require only 0.5 microliters of blood for accurate measurement compliant with ISO 15197:2013 standards, with Bluetooth connectivity to smartphone app. Available in variants including CareSens Dual and CareSens N Premier. Targets individual diabetes patients for at-home glucose self-monitoring.
• CareSens N (케어센스 N) Accessible Blood Glucose Meter

Quantifiable outcome

• Q1 2026 CGM revenue increased 172% YoY to 84 billion KRW
• +3 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability1 record

Feature5 records

Scale indicators14 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Dexcom: Global market leader in standalone continuous glucose monitoring systems (G6/G7). Closest direct competitor to i-SENS CareSens Air in the hospital, retail, and digital-health CGM channel across the US and Europe.
• Abbott Diabetes Care: Operates the FreeStyle Libre franchise, the largest-selling CGM globally. Direct competitor to CareSens Air and the dominant shared-decision point for payers and endocrinologists worldwide.
• LifeScan: Long-standing BGM brand (OneTouch) that has now also entered CGM through a supply partnership with i-SENS for European markets under the OneTouch Vita brand. Direct peer on blood-glucose meters and increasingly on CGM, while also being a key customer.
• Roche Diabetes Care: Operates the Accu-Chek brand of blood glucose meters and integrated diabetes management solutions. Direct competitor to CareSens BGM worldwide and a structural rival for payer-reimbursed BGM and CGM tenders.
• Ascensia Diabetes Care: Owns the Contour Next BGM franchise (acquired from Bayer). Direct competitor in blood glucose meters globally, especially in retail pharmacy and insurance-covered segments where i-SENS's CareSens competes.

Broad incumbents

• Medtronic Diabetes: Sells Guardian CGM systems integrated with its insulin pumps (MiniMed 780G) as part of a broad diabetes portfolio. Competes with i-SENS in CGM but as part of a much wider diabetes-management offering including pumps, consumables, and software.

Regional players

• Sinocare: China's largest blood glucose monitoring and diabetes care device company, with growing presence in Asia-Pacific BGM and emerging CGM. Regional peer competing in the same Chinese and Southeast Asian channels where i-SENS also sells.
• MicroTech Medical: China-based CGM and BGM device manufacturer expanding into Europe and emerging markets. Regional peer with comparable CGM product positioning to CareSens Air and overlapping global payer/distribution channels.

Emerging players

• Ypsomed: Swiss diabetes device company offering mylife Loop CGM-enabled insulin pump systems and BGM accessories. Emerging peer in the CGM/connected-diabetes ecosystem with similar product breadth but smaller global BGM and CGM installed base than incumbents.
• Senseonics: Developer of Eversense, the longest-wear (180-day) implantable continuous glucose monitor. Emerging CGM competitor pursuing a differentiated longer-duration, professional-installed model that competes with i-SENS's CareSens Air 2 on wear duration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@i-sens
• Facebookfacebook.com/ilovecaresens
• LinkedInlinkedin.com/company/i-sens-inc/posts/?feedView=all
• Instagraminstagram.com/caresenskorea

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about i-SENS Inc